Vivek Subbiah: Two back to back futuristic papers in the journal AI In Precision Oncology

Vivek Subbiah shared on LinkedIn:

“Thrilled to have the opportunity to mentor some of the brightest and the best medical students from The Johns Hopkins University School of Medicine!

So excited to announce the publication of two back to back futuristic papers mentoring these amazing students Luke Zhao, Jacob Blum, Arjun Menta, Victor Yang in the journal AI In Precision Oncology.

• Paper 1:

AlphaFold’s Predictive Revolution in Precision Oncology.

• Paper 2:

Decoding Precision Cancer Care: AI’s Evolution from Data to Decision and Recent Breakthroughs.

Appreciate the vision of Editor-in-Chief of the futuristic journal Douglas Flora.”

Source: Vivek Subbiah/LinkedIn

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA).

He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.

Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world.